Observational studyHealth and quality of life outcomes2026
Interpreting patient-reported outcomes after ischemic stroke: defining minimal important difference in EQ-5D across recovery phases.
Observational study in Health and quality of life outcomes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02470624 (Chinese Acute Ischemic Stroke Treatment Outcome Registry), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Chinese Acute Ischemic Stroke Treatment Outcome Registry
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe EQ‑5D is widely applied to measure patient-reported outcomes, yet its minimally important difference (MID) has not been clearly established across distinct recovery phases after stroke. This study aimed to determine phase‑specific MIDs in EQ‑5D following stroke and to explore heterogeneity by estimation method, direction of change, and stroke etiology.
methodsA total of 9978 adults with neuroimaging‑confirmed acute ischemic stroke were included in a prospective longitudinal cohort study. EQ‑5D and modified Rankin Scale (mRS) scores were recorded at admission (V1), hospital discharge (V2), 3-month (V3), and 1-year since admission (V4). Anchor-based MIDs were estimated at both group and individual levels and triangulated by distribution-based and instrument-defined approaches. Changes during the recovery phases (V1–V2, V2–V3, and V3–V4) were grouped into 3 categories: improved, no change, and deteriorated. Subgroup analyses were conducted according to the TOAST classification. Credibility of MID estimates was assessed using a validated instrument for anchor-based methods.
resultsPhase-specific group-level MIDs for improvement decreased over time: anchor-based estimates were 0.19 at V2, 0.14 at V3, and 0.11 at V4, while deterioration MIDs were smaller. Distribution-based and instrument-defined estimates fluctuated slightly around the anchor-based values but followed a similar downward trend over time. Individual‑level analyses yielded MIDs with acceptable discriminative power (area under the curve ≥ 0.70) only for improvement at V2 (0.10) and V3 (0.01). Cardioembolic strokes had higher MIDs than large-artery atherosclerosis and small-artery occlusion, while baseline utilities showed the reverse. Credibility assessment confirmed high reliability.
conclusionThis study provides the phase‑specific MIDs for utility measures after ischemic stroke, showing a declining trend from acute to chronic recovery and confirming robustness across multiple estimation methods. While group‑level MID ranges are recommended for effect size interpretation, trial design, and evidence certainty rating, individual‑level thresholds should be reserved for personalized evaluation. These values assist in the interpretation of patient‑reported outcome changes and evaluation of healthcare interventions across different recovery phases.
trial registrationClinicalTrials.gov NCT02470624. Registered 10 June 2015.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.